Dasatinib-induced AML differentiation requires MEK/ERK-dependent activation of STAT1.

<p>HL60 cells were treated with dasatinib (10 µM) in the presence of PD98059 (20 µM) for 72 h, and NB4 cells were treated with dasatinib (5 µM) in the presence of PD98059 (10 µM) for 48 h. HL60 and NB4 cells were pretreated with PD98059 for 1 h, and then incubated with dasatinb. (A) The percentages of CD11b expression cells were determined as described. Data presented are the mean ± SD of three independent experiments. (B) Cell cycle proportion was analyzed as described. Data presented are the mean ± SD of three independent experiments. *** P<.001, * P<.05. (C) and (D) The expression of p-MEK, p-ERK, p-STAT1(Y701) and p-STAT1(S727) as well as their total proteins in HL60 and NB4 cells were analyzed by Western blotting. The experiments were repeated three times and the data show the representative results.